Session

IBD (Posters)

ASSESSMENT OF VEDOLIZUMAB DISEASE-DRUG-DRUG INTERACTION IN PATIENTS WITH INFLAMMATORY BOWEL DISEASES
ASSESSMENT OF VEDOLIZUMAB DISEASE-DRUG-DRUG INTERACTION IN PATIENTS WITH INFLAMMATORY BOWEL DISEASES

PHYSICIAN PREFERENCES FOR BIOLOGICS FOR THE TREATMENT OF CROHN'S DISEASE AND ULCERATIVE COLITIS IN FRANCE, GERMANY AND THE UNITED KINGDOM
PHYSICIAN PREFERENCES FOR BIOLOGICS FOR THE TREATMENT OF CROHN'S DISEASE AND ULCERATIVE COLITIS IN FRANCE, GERMANY AND THE UNITED KINGDOM

OCCURRENCE OF COLORECTAL CANCER AND THE EFFECT OF MEDICAL TREATMENT IN CROHN'S DISEASE PATIENTS
OCCURRENCE OF COLORECTAL CANCER AND THE EFFECT OF MEDICAL TREATMENT IN CROHN'S DISEASE PATIENTS

THE ASSOCIATION BETWEEN PATIENT ACTIVATION AND HEALTH-RELATED QUALITY OF LIFE AMONG INDIVIDUALS WITH CROHN'S DISEASE
THE ASSOCIATION BETWEEN PATIENT ACTIVATION AND HEALTH-RELATED QUALITY OF LIFE AMONG INDIVIDUALS WITH CROHN'S DISEASE

CHARACTERISTICS OF ULCERATIVE COLITIS PATIENTS BY URGENCY OF DEFECATION AT ENROLLMENT IN THE CORRONA INFLAMMATORY BOWEL DISEASE REGISTRY
CHARACTERISTICS OF ULCERATIVE COLITIS PATIENTS BY URGENCY OF DEFECATION AT ENROLLMENT IN THE CORRONA INFLAMMATORY BOWEL DISEASE REGISTRY

IN FAILURE OF NON-OPTIMIZED ADALIMUMAB (ADA) WITH THERAPEUTIC SERUM LEVELS, A CHANGE IN BIOTHERAPY CLASS IS GREATER THAN AN INTENSIFICATION OF ADA DOSE IN PATIENTS WITH CROHN_S DISEASE AND HEMORRHAGIC RECTOCOLITIS
IN FAILURE OF NON-OPTIMIZED ADALIMUMAB (ADA) WITH THERAPEUTIC SERUM LEVELS, A CHANGE IN BIOTHERAPY CLASS IS GREATER THAN AN INTENSIFICATION OF ADA DOSE IN PATIENTS WITH CROHN_S DISEASE AND HEMORRHAGIC RECTOCOLITIS

EARLY DETECTION OF ANTI-DRUG-ANTIBODIES USING DRUG-TOLERANT ASSAY WITHIN THE INDUCTION PHASE AT WEEK 2 PREDICTS THE LOSS OF CLINICAL RESPONSE TO ANTI-TNF IN INFLAMMATORY BOWEL DISEASE PATIENTS
EARLY DETECTION OF ANTI-DRUG-ANTIBODIES USING DRUG-TOLERANT ASSAY WITHIN THE INDUCTION PHASE AT WEEK 2 PREDICTS THE LOSS OF CLINICAL RESPONSE TO ANTI-TNF IN INFLAMMATORY BOWEL DISEASE PATIENTS

LOW ADHESION TO LATENT TUBERCULOSIS (TB) SCREENING RECOMMENDATIONS IN INFLAMMATORY BOWEL DISEASE (IBD) PATIENTS: RESULTS OF THE INFEII REGISTRY OF GETECCU
LOW ADHESION TO LATENT TUBERCULOSIS (TB) SCREENING RECOMMENDATIONS IN INFLAMMATORY BOWEL DISEASE (IBD) PATIENTS: RESULTS OF THE INFEII REGISTRY OF GETECCU

TREATMENT PATTERNS OF COMPLEX PERIANAL FISTULA IN CROHN'S DISEASE IN BELGIUM, FRANCE, GERMANY, ITALY AND SPAIN: THE PREFACE STUDY, A RETROSPECTIVE CHART REVIEW
TREATMENT PATTERNS OF COMPLEX PERIANAL FISTULA IN CROHN'S DISEASE IN BELGIUM, FRANCE, GERMANY, ITALY AND SPAIN: THE PREFACE STUDY, A RETROSPECTIVE CHART REVIEW

NO BENEFIT OF CONCOMITANT IMMUNOMODULATOR THERAPY ON EFFICACY OF NON - ANTI-TNF BIOLOGICS IN INFLAMMATORY BOWEL DISEASES: A META-ANALYSIS
NO BENEFIT OF CONCOMITANT IMMUNOMODULATOR THERAPY ON EFFICACY OF NON - ANTI-TNF BIOLOGICS IN INFLAMMATORY BOWEL DISEASES: A META-ANALYSIS

FIRST SUCCESSFUL COMPARISON OF QUANTUM BLUE® RAPID TDM ASSAY STANDARDIZATION WITH WHO INTERNATIONAL STANDARD FOR INFLIXIMAB
FIRST SUCCESSFUL COMPARISON OF QUANTUM BLUE® RAPID TDM ASSAY STANDARDIZATION WITH WHO INTERNATIONAL STANDARD FOR INFLIXIMAB

SAFETY AND EFFICACY OF USTEKINUMAB FOR CROHN'S DISEASE (CD): THE CROSS PENNINE EXPERIENCE
SAFETY AND EFFICACY OF USTEKINUMAB FOR CROHN'S DISEASE (CD): THE CROSS PENNINE EXPERIENCE

IGA VASCULITIS ASSOCIATED WITH INFLAMMATORY BOWEL DISEASES: A MULTICENTER STUDY OF THE GETAID AND GFEV
IGA VASCULITIS ASSOCIATED WITH INFLAMMATORY BOWEL DISEASES: A MULTICENTER STUDY OF THE GETAID AND GFEV

ESCHERICHIA COLI GENOTYPES AND BACTERIOCIN PRODUCTION IN THE LARGE BOWEL MUCOSA OF CROHN_S DISEASE AND ULCERATIVE COLITIS
ESCHERICHIA COLI GENOTYPES AND BACTERIOCIN PRODUCTION IN THE LARGE BOWEL MUCOSA OF CROHN_S DISEASE AND ULCERATIVE COLITIS

SCREENING FOR IRON-DEFICIENCY IN NON-ANEMIC PATIENTS WITH IBD: DOES IT MATTER?
SCREENING FOR IRON-DEFICIENCY IN NON-ANEMIC PATIENTS WITH IBD: DOES IT MATTER?

AN UPDATE ON THE ANALYSIS OF NON-MELANOMA SKIN CANCER IN THE TOFACITINIB ULCERATIVE COLITIS CLINICAL PROGRAMME AS OF MAY 2019
AN UPDATE ON THE ANALYSIS OF NON-MELANOMA SKIN CANCER IN THE TOFACITINIB ULCERATIVE COLITIS CLINICAL PROGRAMME AS OF MAY 2019

PROACTIVE THERAPEUTIC DRUG MONITORING IN THE EARLY PHASE OF INFLIXIMAB THERAPY: RESULTS FROM A 30 WEEK MULTICENTRE RANDOMISED TRIAL OF 400 PATIENTS (THE NOR-DRUM STUDY)
PROACTIVE THERAPEUTIC DRUG MONITORING IN THE EARLY PHASE OF INFLIXIMAB THERAPY: RESULTS FROM A 30 WEEK MULTICENTRE RANDOMISED TRIAL OF 400 PATIENTS (THE NOR-DRUM STUDY)

TOFACITINIB FOR THE TREATMENT OF ULCERATIVE COLITIS: AN UPDATED ANALYSIS OF INFECTION RATES IN THE TOFACITINIB ULCERATIVE COLITIS CLINICAL PROGRAMME
TOFACITINIB FOR THE TREATMENT OF ULCERATIVE COLITIS: AN UPDATED ANALYSIS OF INFECTION RATES IN THE TOFACITINIB ULCERATIVE COLITIS CLINICAL PROGRAMME

HERPES ZOSTER INFECTION IN PATIENTS WITH ULCERATIVE COLITIS RECEIVING TOFACITINIB: AN UPDATE AS OF MAY 2019
HERPES ZOSTER INFECTION IN PATIENTS WITH ULCERATIVE COLITIS RECEIVING TOFACITINIB: AN UPDATE AS OF MAY 2019

TOFACITINIB FOR THE TREATMENT OF ULCERATIVE COLITIS: UP TO 6.8 YEARS OF SAFETY DATA FROM GLOBAL CLINICAL TRIALS
TOFACITINIB FOR THE TREATMENT OF ULCERATIVE COLITIS: UP TO 6.8 YEARS OF SAFETY DATA FROM GLOBAL CLINICAL TRIALS

Item 81 - 100 / 558
1 2 3 4
5
6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28